NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a ...

defendants failed to disclose the truth about the failed inspection of Viatris' Indore, India facility, which resulted in the FDA issuing a warning letter and import alert. Specifically ...

Additionally, Viatris successfully repaid $3.7 billion in debt over the fiscal year. However, in a setback, the company received a warning letter and import alert from the U.S. Food and Drug ...

On December 23, 2024, Viatris disclosed that “following an inspection by the U.S. FDA” at the Company’s manufacturing facility in Indore “the Agency has issued a Warning Letter ...

The stock is down significantly so far in 2025. In December 2024, the FDA issued a warning letter and import alert for ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NASDAQ: VTRS) for violations of §§10 ...

NEW YORK - March 31, 2025 ( NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS).

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Viatris Inc. (“Viatris” or the “Company”) ( ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or "the Company") (NASDAQ: VTRS) for ...

Viatris misled investors about the severity ... The Company misrepresented the nature of the FDA’s warning letter and downplayed the warning’s impact on its operation. The Company claimed ...